Tesar V, Zima T, Jirsa M, Crkovská J, Stípek S, Vernerová Z, Seráková M
I. interní klinika 1. LF UK a VFN, Praha.
Cas Lek Cesk. 1999 Oct 20;138(18):560-4.
Increased permeability of glomerular capillary wall in adriamycin nephropathy may be mediated by increased generation of free radicals and possibly also by the non-enzymatic production of isoprostanes induced by oxidative stress. ACE inhibitors may reduce proteinuria, possibly due to the decrease of intraglomerular pressure and increased permselectivity of the glomerular capillary wall. These effects may be partly mediated by the inhibition of the degradation of kinins. It is not clear if newly available angiotensin II antagonists have the same antiproteinuric and renoprotective effects.
We compared the effect of an ACE inhibitor (enalapril, 0.4 mg/kg bw i.p. daily for 3 weeks) and angiotensin II antagonist (losartan, 2 mg/kg bw in the same way) on experimental nephrotic syndrome induced in rats by the administration of adriamycin (5 mg/kg bw i.v. in a single dose). To elucidate the potential differences between these two drugs we also measured total malondialdehyde in blood and urinary excretion some eicosanoids and their metabolites (TxB2, 6-keto-PGF1alfa, bicyclo-PGE2 and 8-isoprostane). Proteinuria increased in adriamycin treated rats after 3 weeks from 0.18 +/- 0.01 to 0.44 +/- 0.14 g/mmol creat, p < 0.01. This increase was not prevented by losartan (increase from 0.18 +/- 0.12 to 0.50 +/- 0.11 g/mmol creat, p < 0.05), but tended to be partly blunted by enalapril (increase from 0.20 +/- 0.10 to only 0.32 +/- 0.08 g/mmol creat, p < 0.05). Similarly there was no increase of serum cholesterol, only in enalapril treated rats. On the other hand, both losartan (1.27 +/- 0.13 vs. 1.91 +/- 0.30 mumol/l, p < 0.05) and enalapril (0.93 +/- 0.06 mumol/l, p < 0.001) prevented adriamycin induced increase of total MDA in serum, but urinary excretion of 8-isoprostane was increased in nephrotic rats treated by losartan compared to controls. Enalapril induced increase of urinary excretion of bicyclo-PGE2 (4.32 +/- 0.62 vs. 1.66 +/- 0.81 ng/mmol creat, p < 0.001) was possibly mediated by kinins. There was no significant difference in the urinary excretion of other eicosanoids between different groups, but proteinuria correlated positively with urinary excretion of 8-isoprostane (p < 0.01). Proteinuric rats had also significantly higher urinary excretion of 8-isoprostane than non-proteinuric rats (44.8 +/- 7.1 vs. 26.7 +/- 3.4 ng/mmol. creat, p < 0.05).
Our data suggest that proteinuria in adriamycin nephropathy may mainly depend on free radical generation and the formation of 8-isoprostane. Haemodynamic parameters (glomerular pressure) do not seem to be so important. The mild antiproteinuric effect of enalapril may suggest a contributory role of the inhibition of kinin degradation in this model of nephrotic syndrome.
阿霉素肾病中肾小球毛细血管壁通透性增加可能由自由基生成增加介导,也可能由氧化应激诱导的异前列腺素非酶生成介导。血管紧张素转换酶(ACE)抑制剂可能会降低蛋白尿,这可能是由于肾小球内压降低以及肾小球毛细血管壁的滤过选择性增加。这些作用可能部分由激肽降解抑制介导。目前尚不清楚新上市的血管紧张素II拮抗剂是否具有相同的抗蛋白尿和肾脏保护作用。
我们比较了ACE抑制剂(依那普利,每日腹腔注射0.4mg/kg体重,共3周)和血管紧张素II拮抗剂(氯沙坦,以相同方式给药,2mg/kg体重)对阿霉素(单次静脉注射5mg/kg体重)诱导的大鼠实验性肾病综合征的影响。为了阐明这两种药物之间的潜在差异,我们还测量了血液中总丙二醛以及一些类花生酸及其代谢产物(血栓素B2、6-酮-前列腺素F1α、双环前列腺素E2和8-异前列腺素)的尿排泄量。阿霉素处理的大鼠在3周后蛋白尿从0.18±0.01增加至0.44±0.14g/mmol肌酐,p<0.01。氯沙坦未能阻止这种增加(从0.18±0.12增加至0.50±0.11g/mmol肌酐,p<0.05),但依那普利使其增加趋势有所减弱(从0.20±0.10仅增加至0.32±0.08g/mmol肌酐,p<0.05)。同样,仅在依那普利处理的大鼠中血清胆固醇没有增加。另一方面,氯沙坦(1.27±0.13对1.91±0.30μmol/l,p<0.05)和依那普利(0.93±0.06μmol/l,p<0.001)均阻止了阿霉素诱导的血清总丙二醛增加,但与对照组相比,氯沙坦处理的肾病大鼠8-异前列腺素的尿排泄量增加。依那普利诱导的双环前列腺素E2尿排泄量增加(4.32±0.62对1.66±0.81ng/mmol肌酐,p<0.001)可能由激肽介导。不同组之间其他类花生酸的尿排泄量没有显著差异,但蛋白尿与8-异前列腺素的尿排泄量呈正相关(p<0.01)。蛋白尿大鼠的8-异前列腺素尿排泄量也显著高于无蛋白尿大鼠(44.8±7.1对26.7±3.4ng/mmol肌酐,p<0.05)。
我们的数据表明,阿霉素肾病中的蛋白尿可能主要取决于自由基生成和8-异前列腺素的形成。血流动力学参数(肾小球压力)似乎并非如此重要。依那普利的轻度抗蛋白尿作用可能表明在这种肾病综合征模型中抑制激肽降解起到了一定作用。